28,717 Shares in Pediatrix Medical Group, Inc. (NYSE:MD) Acquired by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC purchased a new position in Pediatrix Medical Group, Inc. (NYSE:MD) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 28,717 shares of the company’s stock, valued at approximately $377,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of MD. Pacer Advisors Inc. acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter worth approximately $35,492,000. Weiss Asset Management LP grew its stake in shares of Pediatrix Medical Group by 50.5% during the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after purchasing an additional 306,143 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Pediatrix Medical Group during the 4th quarter worth approximately $3,066,000. RBF Capital LLC acquired a new stake in shares of Pediatrix Medical Group during the 3rd quarter worth approximately $1,695,000. Finally, Rubric Capital Management LP grew its stake in shares of Pediatrix Medical Group by 1.5% during the 3rd quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after purchasing an additional 125,000 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Trading Up 4.0 %

Shares of MD stock opened at $14.26 on Tuesday. The stock’s fifty day moving average is $14.19 and its two-hundred day moving average is $13.45. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.42 and a current ratio of 1.60. The firm has a market capitalization of $1.22 billion, a P/E ratio of -11.89, a PEG ratio of 1.74 and a beta of 1.49. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $17.67.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.37 by $0.12. Pediatrix Medical Group had a positive return on equity of 15.47% and a negative net margin of 4.92%. The business had revenue of $502.36 million for the quarter, compared to analyst estimates of $486.22 million. Research analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

MD has been the topic of a number of research analyst reports. Macquarie initiated coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target on the stock. UBS Group lifted their price target on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the company a “neutral” rating in a research note on Friday, February 21st. Truist Financial lifted their price target on shares of Pediatrix Medical Group from $15.00 to $18.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of “Hold” and a consensus target price of $17.08.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.